SCHEMBL6375968

SCHEMBL6375968

CC(C)(C)OC(=O)C[C@H](CN)Cc1ccco1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
ALDH1A1 P00352 7/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MAPT P10636 4/20 0.39
HPGD P15428 3/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
RIPK1 Q13546 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
ALOX5 P09917 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6375958 1.00 CTSS (0.46) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL6376094 1.00 CTSS (0.46) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL6376518 0.88 CTSS (0.46) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL6376162 0.88 CTSS (0.46) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL6376155 0.88 CTSS (0.46) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL6376057 0.80 CTSS (0.49) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL1915719 0.80 CTSS (0.49) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL1914911 0.80 CTSS (0.49) CTSSCTSKALDH1A1SMN1; SMN2MAPT
SCHEMBL6382413 0.79 MIF (0.45) ALDH1A1MAPTHPGDGAANPC1
SCHEMBL6375241 0.79 MIF (0.45) ALDH1A1MAPTHPGDGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1185524-B1 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS WARNER LAMBERT CO (US) 2005-01-26 EP claimed
US-6710190-B1 ANTIEPILEPTIC, ANTIDEPRESSANT, ANXIOLYTIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANALGESIC AGENTS; NEURODEGENERATIVE AND GASTROINTESTINAL DISORDERS; IRRITABLE BOWEL SYNDROME WARNER-LAMBERT COMPANY 2004-03-23 US claimed
JP-2003500486-A 2003-01-07 JP claimed
EP-1185524-A2 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS WARNER-LAMBERT COMPANY (US) 2002-03-13 EP claimed
WO-2000073296-A2 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS WARNER-LAMBERT COMPANY (US) 2000-12-07 WO claimed
EP-1185524-B1 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS WARNER LAMBERT CO (US) 2005-01-26 EP disclosed
US-6833385-B2 Thiophene derivatives; epilepsy, faintness attacks, depression, anxiety, panic, pain; neurodegenerative, neuropathological and gastrointestinal disorders WARNER-LAMBERT COMPANY 2004-12-21 US disclosed
US-20040127724-A1 3-heteroarylalkyl substituted GABA analogs YUEN PO-WAI (US) 2004-07-01 US disclosed
US-6710190-B1 ANTIEPILEPTIC, ANTIDEPRESSANT, ANXIOLYTIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANALGESIC AGENTS; NEURODEGENERATIVE AND GASTROINTESTINAL DISORDERS; IRRITABLE BOWEL SYNDROME WARNER-LAMBERT COMPANY 2004-03-23 US disclosed
EP-1185524-A2 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS WARNER-LAMBERT COMPANY (US) 2002-03-13 EP disclosed
WO-2000073296-A2 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS WARNER-LAMBERT COMPANY (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127724-A1 3-heteroarylalkyl substituted GABA analogs GABRB3, GABRB1, GABRB2 CTSS 423/4885CTSK 923/4885ALDH1A1 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.